Show simple item record

dc.contributor.authorLeón D.
dc.contributor.authorBuchegger K.
dc.contributor.authorSilva R.
dc.contributor.authorRiquelme I.
dc.contributor.authorViscarra T.
dc.contributor.authorMora-Lagos B.
dc.contributor.authorZanella L.
dc.contributor.authorSchafer F.
dc.contributor.authorKurachi C.
dc.contributor.authorRoa J.C.
dc.contributor.authorIli C.
dc.contributor.authorBrebi P.
dc.date.accessioned2020-09-02T22:21:43Z
dc.date.available2020-09-02T22:21:43Z
dc.date.issued2020
dc.identifier10.3390/ijms21093327
dc.identifier.citation21, 9, -
dc.identifier.issn16616596
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5073
dc.descriptionPhotodynamic therapy (PDT) has been used to treat certain types of non-melanoma skin cancer with promising results. However, some skin lesions have not fully responded to this treatment, suggesting a potential PDT-resistant phenotype. Therefore, novel therapeutic alternatives must be identified that improve PDT in resistant skin cancer. In this study, we analyzed the cell viability, intracellular protoporphyrin IX (PpIX) content and subcellular localization, proliferation profile, cell death, reactive oxygen species (ROS) detection and relative gene expression in PDT-resistant HSC-1 cells. PDT-resistant HSC-1 cells show a low quantity of protoporphyrin IX and low levels of ROS, and thus a low rate of death cell. Furthermore, the resistant phenotype showed a downregulation of HSPB1, SLC15A2, FECH, SOD2 and an upregulation of HMBS and BIRC5 genes. On the other hand, epigallocatechin gallate catechin enhanced the MAL-PDT effect, increasing levels of protoporphyrin IX and ROS, and killing 100% of resistant cells. The resistant MAL-PDT model of skin cancer squamous cells (HSC-1) is a reliable and useful tool to understand PDT cytotoxicity and cellular response. These resistant cells were successfully sensitized with epigallocatechin gallate catechin. The in vitro epigallocatechin gallate catechin effect as an enhancer of MAL-PDT in resistant cells is promising in the treatment of difficult skin cancer lesions. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
dc.language.isoen
dc.publisherMDPI AG
dc.subjectMethyl aminolevulinate
dc.subjectNon-melanoma skin cancer
dc.subjectPhotodynamic therapy
dc.subjectSquamous cell carcinoma
dc.subjectcatechin
dc.subjectepigallocatechin gallate
dc.subjectphosphatidylserine
dc.subjectprotoporphyrin
dc.subjectreactive oxygen metabolite
dc.subjectsurvivin
dc.subjectantioxidant activity
dc.subjectapoptosis
dc.subjectArticle
dc.subjectcancer resistance
dc.subjectcell culture
dc.subjectcell death
dc.subjectcell metabolism
dc.subjectcell proliferation
dc.subjectcell stress
dc.subjectcell survival
dc.subjectcell viability
dc.subjectcellular distribution
dc.subjectclonogenic assay
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectcytometry
dc.subjectcytotoxicity
dc.subjectdown regulation
dc.subjectenzyme activity
dc.subjectflow cytometry
dc.subjectgene expression
dc.subjectgene sequence
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthypoxia
dc.subjectMTT assay
dc.subjectphenotype
dc.subjectphotodynamic therapy
dc.subjectprotein expression
dc.subjectreal time reverse transcription polymerase chain reaction
dc.subjectRNA extraction
dc.subjectskin carcinoma
dc.subjectupregulation
dc.subjectwound closure
dc.subjectwound healing assay
dc.titleEpigallocatechin gallate enhances MAL-PDT cytotoxic effect on PDT-resistant skin cancer squamous cells
dc.typeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record